Vir Biotechnology

Vir Biotechnology logo
🇺🇸United States
Ownership
Public
Established
2016-04-07
Employees
587
Market Cap
-
Website
http://www.vir.bio
Introduction

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

benzinga.com
·

What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?

Vir Biotechnology announced end-of-treatment data from MARCH Phase 2 study, showing promising HBsAg loss rates with tobevibart and elebsiran combinations in chronic hepatitis B patients, with 39% and 46% HBsAg loss in low baseline HBsAg participants for doublet and triplet regimens, respectively.
marketscreener.com
·

Vir Biotechnology, Inc. Announces Positive End-Of-T Treatment Results for Tobevibart and ...

Vir Biotechnology's MARCH Phase 2 study showed promising HBsAg loss rates with tobevibart and elebsiran combinations, particularly in participants with low baseline HBsAg. The doublet and triplet regimens achieved HBsAg loss in 39% and 46% of participants with HBsAg <1,000 IU/mL, respectively. Safety profiles were consistent with prior studies, supporting further development for functional cure evaluation.
stocktitan.net
·

Vir Bio's Hepatitis B Treatment Shows 46% Success Rate in Key Clinical Trial

Vir Biotechnology announced positive end-of-treatment results from the MARCH Phase 2 study, showing 39% HBsAg loss with tobevibart + elebsiran and 46% with the triplet regimen in low baseline HBsAg patients. No new safety concerns were identified, with mild to moderate adverse events. Key functional cure data is expected in Q2 2025.
marketscreener.com
·

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart

39% of participants with low baseline HBsAg achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated interferon alfa. No new safety concerns were identified, and treatment-emergent adverse events were generally mild to moderate. MARCH Part B study results presented at AASLD The Liver Meeting®. Key functional cure data from 24-week follow-up expected in Q2 2025.
markets.ft.com
·

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and ...

39% of low baseline HBsAg participants achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated interferon alfa. No new safety concerns were identified, and TEAEs were generally mild to moderate. MARCH Part B study results were presented at AASLD The Liver Meeting®. Key functional cure data from 24-week follow-up expected in Q2 2025.
investing.com
·

Promising hepatitis B treatment data presented by Vir Biotechnology

Vir Biotechnology's Phase 2 trial for chronic hepatitis B treatment showed significant HBsAg loss rates with tobevibart and elebsiran, with or without pegylated interferon alfa. The company aims for a functional cure by Q2 2025, with ongoing progress in hepatitis programs and T-cell engager trials. Financial stability and strategic restructuring support continued R&D efforts despite revenue challenges.
timmermanreport.com
·

Save the Date: TR 10th Anniversary

Timmerman Report celebrates its 10th anniversary with events in Boston (Mar. 6) and Seattle (Mar. 13), featuring biotech leaders discussing future trends in biopharma.

Hold Recommendation for Vir Biotechnology Amid Cautious Optimism on Infectious Disease

J.P. Morgan analyst Eric Joseph maintains a Hold rating on Vir Biotechnology (VIR) stock, balancing cautious optimism about its infectious disease treatments and oncology assets, with a focus on upcoming phase 2 trial results.
tradingview.com
·

Vir Biotechnology EVP Vanina De Verneuil Sells Shares

Vanina De Verneuil, EVP and General Counsel at Vir Biotechnology, sold 4,397 shares for $44,453 on Nov 6, 2024, leaving her with 56,973 shares. The sale was under a Rule 10b5-1 plan adopted on Aug 5, 2024.
© Copyright 2024. All Rights Reserved by MedPath